Michael Heffernan
About Michael Heffernan
Michael Heffernan is a seasoned biopharmaceutical leader and entrepreneur with extensive experience in founding and managing companies in the healthcare sector.
Michael Heffernan: Founder and Chairman
Michael Heffernan is the Founder and Chairman, best known for his significant contributions to the biopharmaceutical industry. He has a distinguished career spanning over 25 years, where he has established and led numerous development-stage and commercial companies. His leadership has been instrumental in the growth and success of several pioneering firms in the industry.
Michael Heffernan's Education in Pharmacy
Michael Heffernan earned a Bachelor of Science degree in Pharmacy from the University of Connecticut. His educational background in pharmacy set the foundation for his extensive career in the biopharmaceutical sector. This degree equipped him with the necessary knowledge and skills to innovate and lead in his field.
Michael Heffernan's Entrepreneurial and Biopharmaceutical Leadership
Michael Heffernan is acclaimed for his entrepreneurial spirit and leadership in the biopharmaceutical industry. He has over 25 years of experience and has been instrumental in founding and managing several companies. Some of his notable roles include President and CEO of Collegium Pharmaceutical, CEO of Onset Dermatologics, and Co-Founder and CEO of Clinical Studies Ltd. His ventures in these roles have had significant impacts on the industry.
Michael Heffernan's Role in Immuno-Oncology with Avenge Bio
Michael Heffernan co-founded Avenge Bio, a company dedicated to immuno-oncology. He remains actively involved in managing the company, focusing on advancing therapeutic solutions in the fight against cancer. His role at Avenge Bio highlights his continued commitment to groundbreaking research and development in the field of biopharmaceuticals.
Michael Heffernan's Board Memberships
Michael Heffernan serves on the board of directors of several companies, showcasing his extensive influence and leadership. His current board memberships include Akebia Therapeutics, Inc. (AKBA), Trevi Therapeutics, Inc. (TRVI), Biohaven Pharmaceutical Holding Company Ltd. (BHVN), and Synlogic, Inc. (SYBX). He has also served on the boards of Keryx Biopharmaceuticals, Inc., Ocata Therapeutics, Inc. (OCAT), Cornerstone Therapeutics Inc. (CRTX), and Veloxis Pharmaceuticals A/S. Additionally, he is involved with several privately held companies.